VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, unveiled its first in vivo proof-of-concept data and additional in vitro findings for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The announcement marks a critical milestone for the company and the broader oncology field, as it provides early validation of a next-generation antibody-drug conjugate (ADC) approach that could address long-standing challenges in cancer treatment.
The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. Importantly, the results showed that both BiTAC-ADC components were required to produce the intended tumor-specific response. This finding underscores the platform's precision: the therapy is designed to activate only when both components engage their targets, potentially minimizing off-tumor effects. Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines. These results support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional ADCs while offering a differentiated safety profile designed to reduce systemic toxicity.
The implications of these findings are substantial. Conventional ADCs, while effective, often suffer from systemic toxicity due to premature release of cytotoxic payloads outside tumor cells, leading to dose-limiting side effects. By engineering a platform that requires dual targeting for activation, VERAXA aims to widen the therapeutic window, potentially allowing for higher doses and better patient outcomes. The observed tumor regression with no weight loss in animal models is an encouraging early sign of tolerability. If these results translate to human trials, BiTAC-ADCs could become a safer alternative for patients who cannot tolerate current ADC therapies.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline into clinical development and beyond. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
For investors, the presentation at the World ADC Congress provides tangible evidence of progress and could boost confidence in the company's technology. To view the full press release, visit https://ibn.fm/cs8SW. The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA.
The announcement is being amplified through BillionDollarClub (BDC), a specialized communications platform with a focus on the biggest and brightest companies covered by IBN. BDC is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
